These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 27366944)

  • 21. c-JUN N-terminal kinase (JNK) is activated and contributes to tumor cell proliferation in classical Hodgkin lymphoma.
    Leventaki V; Drakos E; Karanikou M; Psatha K; Lin P; Schlette E; Eliopoulos A; Vassilakopoulos TP; Papadaki H; Patsouris E; Medeiros LJ; Rassidakis GZ
    Hum Pathol; 2014 Mar; 45(3):565-72. PubMed ID: 24457077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular Pathogenesis of Hodgkin Lymphoma: Past, Present, Future.
    Bienz M; Ramdani S; Knecht H
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32927751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hodgkin lymphoma: Pathology and biology.
    Mathas S; Hartmann S; Küppers R
    Semin Hematol; 2016 Jul; 53(3):139-47. PubMed ID: 27496304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional coexpression of Interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: Involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma.
    Cattaruzza L; Gloghini A; Olivo K; Di Francia R; Lorenzon D; De Filippi R; Carbone A; Colombatti A; Pinto A; Aldinucci D
    Int J Cancer; 2009 Sep; 125(5):1092-101. PubMed ID: 19391137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma.
    Sánchez-Espiridión B; Martín-Moreno AM; Montalbán C; Figueroa V; Vega F; Younes A; Medeiros LJ; Alvés FJ; Canales M; Estévez M; Menarguez J; Sabín P; Ruiz-Marcellán MC; Lopez A; Sánchez-Godoy P; Burgos F; Santonja C; López JL; Piris MA; Garcia JF
    Br J Haematol; 2013 Aug; 162(3):336-47. PubMed ID: 23725219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome.
    Chetaille B; Bertucci F; Finetti P; Esterni B; Stamatoullas A; Picquenot JM; Copin MC; Morschhauser F; Casasnovas O; Petrella T; Molina T; Vekhoff A; Feugier P; Bouabdallah R; Birnbaum D; Olive D; Xerri L
    Blood; 2009 Mar; 113(12):2765-3775. PubMed ID: 19096012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Profiling of Hodgkin's lymphoma cell line L1236 and germinal center B cells: identification of Hodgkin's lymphoma-specific genes.
    Schwering I; Bräuninger A; Distler V; Jesdinsky J; Diehl V; Hansmann ML; Rajewsky K; Küppers R
    Mol Med; 2003; 9(3-4):85-95. PubMed ID: 12865944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization.
    Hartmann S; Martin-Subero JI; Gesk S; Hüsken J; Giefing M; Nagel I; Riemke J; Chott A; Klapper W; Parrens M; Merlio JP; Küppers R; Bräuninger A; Siebert R; Hansmann ML
    Haematologica; 2008 Sep; 93(9):1318-26. PubMed ID: 18641027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line.
    Baus D; Nonnenmacher F; Jankowski S; Döring C; Bräutigam C; Frank M; Hansmann ML; Pfitzner E
    Leukemia; 2009 Oct; 23(10):1885-93. PubMed ID: 19440213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.
    Hao Y; Chapuy B; Monti S; Sun HH; Rodig SJ; Shipp MA
    Clin Cancer Res; 2014 May; 20(10):2674-83. PubMed ID: 24610827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis.
    Carbone A; Gloghini A; Caruso A; De Paoli P; Dolcetti R
    Int J Cancer; 2017 Mar; 140(6):1233-1245. PubMed ID: 27750386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.
    Carbone A; Gloghini A; Castagna L; Santoro A; Carlo-Stella C
    J Pathol; 2015 Sep; 237(1):4-13. PubMed ID: 25953622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.
    Chen R; Herrera AF; Hou J; Chen L; Wu J; Guo Y; Synold TW; Ngo VN; Puverel S; Mei M; Popplewell L; Yi S; Song JY; Tao S; Wu X; Chan WC; Forman SJ; Kwak LW; Rosen ST; Newman EM
    Clin Cancer Res; 2020 Mar; 26(5):1034-1044. PubMed ID: 31811017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells.
    Zahn M; Marienfeld R; Melzner I; Heinrich J; Renner B; Wegener S; Mießner A; Barth TF; Dorsch K; Brüderlein S; Möller P
    Blood; 2017 Mar; 129(11):1480-1490. PubMed ID: 28082443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
    Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
    Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells.
    Baus D; Pfitzner E
    Int J Cancer; 2006 Mar; 118(6):1404-13. PubMed ID: 16206268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphoma.
    Xiao Q; Shen N; Hedvat CV; Moskowitz CH; Sussman LK; Filippa DA; Zelenetz AD; Houldsworth J; Chaganti RS; Teruya-Feldstein J
    Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):211-5. PubMed ID: 15551733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FOXO1 is a tumor suppressor in classical Hodgkin lymphoma.
    Xie L; Ushmorov A; Leithäuser F; Guan H; Steidl C; Färbinger J; Pelzer C; Vogel MJ; Maier HJ; Gascoyne RD; Möller P; Wirth T
    Blood; 2012 Apr; 119(15):3503-11. PubMed ID: 22343918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Occurrence of minimal change nephrotic syndrome in classical Hodgkin lymphoma is closely related to the induction of c-mip in Hodgkin-Reed Sternberg cells and podocytes.
    Audard V; Zhang SY; Copie-Bergman C; Rucker-Martin C; Ory V; Candelier M; Baia M; Lang P; Pawlak A; Sahali D
    Blood; 2010 May; 115(18):3756-62. PubMed ID: 20200355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.
    Schmitz R; Hansmann ML; Bohle V; Martin-Subero JI; Hartmann S; Mechtersheimer G; Klapper W; Vater I; Giefing M; Gesk S; Stanelle J; Siebert R; Küppers R
    J Exp Med; 2009 May; 206(5):981-9. PubMed ID: 19380639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.